Clinuvel Sets December 2026 Readout for Vitiligo Drug, Plans Pivotal Trial
CUVL sits 17% above its 52-week low of $5.98 on light trading volume (0.4× avg).
Summary
Clinuvel announced that topline results from its CUV105 vitiligo study are expected in December 2026, and the pivotal CUV107 Phase III trial is planned to start in November 2026 following EMA protocol review.
Key Events · Product Development and Regulatory · CUVL
-
CUV105 Topline Results in December 2026
The 210-patient CUV105 study evaluating SCENESSE with NB-UVB in darker-skinned vitiligo patients will report topline results in December 2026, with primary endpoint T-VASI50 and secondary endpoint F-VASI75.
-
Pivotal CUV107 Phase III to Start November 2026
Following EMA protocol review in April 2026, the pivotal CUV107 study is planned to start in November 2026, enrolling 300 patients with Fitzpatrick skin types IV-VI over a 12-month recruitment period.
-
Regulatory Path Defined
The EMA reviewed and advised on the CUV107 protocol design, and the company noted that SCENESSE's existing marketing authorization for EPP provides a head start for future vitiligo reviews.
-
Strategic Context: U.S. Focus Restructuring
This update follows a July 23, 2026 announcement of a strategic reorganization to focus on the U.S. market, including a 10-20% workforce reduction, highlighting the importance of the vitiligo program to the company's future.
Analysis · CUVL · Unknown
A concrete near-term catalyst has emerged for SCENESSE in vitiligo, a key pipeline asset: topline results from the CUV105 Phase II/III study are now expected in December 2026. The regulatory path is also taking shape, as the EMA reviewed the protocol for the pivotal CUV107 Phase III study, which is planned to start in November 2026 and enroll 300 patients. This filing crystallizes the timelines for a drug that could address a large unmet need in vitiligo, particularly in darker-skinned patients. The update comes just days after the company announced a strategic restructuring to focus on the U.S. market, underscoring the importance of this program to its future.
At the time of this filing, CUVL was trading at $7.00 on NASDAQ in the Unknown sector, with a market capitalization of approximately $345.7M. The 52-week trading range was $5.98 to $9.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.